Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 591 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07483359RecruitingPhase 2
Combination therapy for advanced liver cancer with portal vein tumor thrombus
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
Shenyang, LiaoningAges 18–80 - NCT06624189Enrolling by invitation
Liver cancer screening decision support for cirrhosis patients
This trial tests a tool to help doctors and patients decide when to screen for liver cancer. It is for people with cirrhosis who have not had imaging in the last 6 months.
New York, New YorkAges 18 years+ - NCT06849180Recruiting
Personalized Treatment for Advanced Combined Liver Cancer
This study is for people with a rare and advanced liver cancer called combined hepatocellular cholangiocarcinoma (CHC). Doctors will use information from your tumor and health history to find the best treatment approach for your specific cancer type.
Nanjing, JiangsuAges 18 years+ - NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT04595864RecruitingPhase 3
Chemotherapy into the liver before transplant for liver cancer
This trial tests whether giving chemotherapy directly into the liver blood supply before a liver transplant can help people with liver cancer that is beyond standard transplant criteria. It may help lower cancer risk around the time of transplant while keeping people healthy enough to receive the transplant.
Nanjing, JiangsuAges 18–75 - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT03823144Recruiting
Imaging small live tumor details during surgery
This study uses a special camera to look at solid tumors from inside the body during an operation. It tests whether “live” tumor imaging (using a medicine called fluorescein) can be safely performed in people with certain solid cancers.
Jacksonville, FloridaAges 18 years+ - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Aurora, ColoradoAges 18 years+ - NCT05705492RecruitingPhase 2
Olanzapine to help cancer-related weight and appetite loss
This Phase 2 trial tests whether olanzapine can help people with advanced cancer who are losing weight and not eating enough. It looks for improvements in appetite and weight while you receive your first-line palliative cancer treatment.
Portland, OregonAges 18 years+ - NCT04510129Recruiting
Cancer biospecimen collection study for immunotherapy patients
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
San Francisco, CaliforniaAges 18 years+ - NCT05201404RecruitingPhase 3
Namodenoson for advanced liver cancer with moderate cirrhosis
This Phase 3 trial studies whether namodenoson can slow or control advanced hepatocellular carcinoma (liver cancer) in people whose cirrhosis is in a specific middle range. It may help if standard treatments have not worked or the cancer has spread and is not expected to be cured.
Dallas, TexasAges 18 years+ - NCT05375370Recruiting
Testing a blood test to predict liver cancer coming back
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
RouenAges 18 years+ - NCT05738980Recruiting
Reduce liver cancer return after surgery using anti–TIM-3
This trial studies whether blocking TIM-3 (an immune “brake”) can help stop hepatocellular carcinoma (liver cancer) from coming back after a curative surgery. It may help by improving your immune system’s ability to find and control remaining cancer cells.
Beijing, Beijing MunicipalityAges 18–75 - NCT06961526Recruiting
Preventing varices bleeding in liver cancer patients on immunotherapy
This trial tests if preventing esophageal varices (swollen veins in the food pipe) can reduce bleeding risk in people with advanced liver cancer who are receiving a combination of two drugs (atezolizumab and bevacizumab). It may help those with good liver function and no high-risk varices at the start.
Tanta, GharbyeaAges 18 years+ - NCT07047586RecruitingPhase 2
Lenvatinib plus Tislelizumab vs Lenvatinib alone for liver cancer
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07100392RecruitingPhase 2
A new drug combo for advanced liver cancer after first treatment fails
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07147101Recruiting
Immunotherapy for advanced liver cancer: a study on effectiveness and immune response
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07436845Recruiting
Emotion and treatment for advanced liver cancer
This trial studies if emotional health affects how well targeted therapy and immunotherapy work for people with advanced liver cancer. You will receive chemotherapy directly into the liver along with targeted drugs and immunotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT06157060Recruiting
Predicting liver cancer return after surgery with a blood test
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
Foshan, GuangdongAges 18–75 - NCT06628661Recruiting
Liver cancer surgery: long-term outcomes by tumor size
This study looks at people with a single liver cancer tumor that can be removed by surgery. It checks how tumor size (especially larger than 6.5 cm) and signs of tumor invasion into blood vessels affect long-term outcomes over 10 years.
TaoyuanAges 18–80 - NCT06938945Recruiting
Symptom Tracking App for Liver Cancer Immunotherapy
This trial tests whether using a smartphone app to regularly report your symptoms can help you and your doctor manage side effects better during immunotherapy treatment for liver cancer. It is a study where you would be randomly assigned to either use the app or receive usual care.
Haidian, Beijing MunicipalityAges 18–75 - NCT07141056Recruiting
Emotional stress and immunotherapy for liver cancer
This study looks at how emotional stress affects how well immunotherapy works for liver cancer. It is for people with liver cancer who are about to start immunotherapy, either before or after surgery, or as first treatment for advanced cancer.
Zhanjiang, GuangdongAges 18 years+
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 591 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.